The Effects of Ivabradine on Levcromakalim-induced Migraine
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Hyperpolarization-activated cation (HCN) channels have recently been implicated in
neuropathic and inflammatory pain processes, and HCN channel activity is modulated by
signalling molecules, such as cyclic nucleotides (cAMP, cGMP) and extracellular potassium,
known to induce migraine. To uncover the role of HCN channels in migraine, the researchers
will investigate the anti-migraine effect of ivabradine, the only HCN channel blocker
available for clinical use, on levcromakalim-induced migraine.